190 related articles for article (PubMed ID: 33947863)
21. Human T-ALL Xenografts.
Fuentes P; Toribio ML; González-García S
Methods Mol Biol; 2021; 2185():215-239. PubMed ID: 33165851
[TBL] [Abstract][Full Text] [Related]
22. Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities.
Cappelli LV; Fiore D; Phillip JM; Yoffe L; Di Giacomo F; Chiu W; Hu Y; Kayembe C; Ginsberg M; Consolino L; Barcia Duran JG; Zamponi N; Melnick AM; Boccalatte F; Tam W; Elemento O; Chiaretti S; Guarini A; Foà R; Cerchietti L; Rafii S; Inghirami G
Blood; 2023 Feb; 141(5):503-518. PubMed ID: 35981563
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.
Silva A; Almeida ARM; Cachucho A; Neto JL; Demeyer S; de Matos M; Hogan T; Li Y; Meijerink J; Cools J; Grosso AR; Seddon B; Barata JT
Blood; 2021 Sep; 138(12):1040-1052. PubMed ID: 33970999
[TBL] [Abstract][Full Text] [Related]
24. A data-independent acquisition-based global phosphoproteomics system enables deep profiling.
Kitata RB; Choong WK; Tsai CF; Lin PY; Chen BS; Chang YC; Nesvizhskii AI; Sung TY; Chen YJ
Nat Commun; 2021 May; 12(1):2539. PubMed ID: 33953186
[TBL] [Abstract][Full Text] [Related]
25. MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance.
van der Zwet JCG; Buijs-Gladdines JGCAM; Cordo' V; Debets DO; Smits WK; Chen Z; Dylus J; Zaman GJR; Altelaar M; Oshima K; Bornhauser B; Bourquin JP; Cools J; Ferrando AA; Vormoor J; Pieters R; Vormoor B; Meijerink JPP
Leukemia; 2021 Dec; 35(12):3394-3405. PubMed ID: 34007050
[TBL] [Abstract][Full Text] [Related]
26. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness.
Liu L; Tao T; Liu S; Yang X; Chen X; Liang J; Hong R; Wang W; Yang Y; Li X; Zhang Y; Li Q; Liang S; Yu H; Wu Y; Guo X; Lai Y; Ding X; Guan H; Wu J; Zhu X; Yuan J; Li J; Su S; Li M; Cai X; Cai J; Tian H
Nat Commun; 2021 May; 12(1):2693. PubMed ID: 33976158
[TBL] [Abstract][Full Text] [Related]
27. A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer.
Bassez A; Vos H; Van Dyck L; Floris G; Arijs I; Desmedt C; Boeckx B; Vanden Bempt M; Nevelsteen I; Lambein K; Punie K; Neven P; Garg AD; Wildiers H; Qian J; Smeets A; Lambrechts D
Nat Med; 2021 May; 27(5):820-832. PubMed ID: 33958794
[TBL] [Abstract][Full Text] [Related]
28. Integrated OMICs unveil the bone-marrow microenvironment in human leukemia.
Passaro D; Garcia-Albornoz M; Diana G; Chakravarty P; Ariza-McNaughton L; Batsivari A; Borràs-Eroles C; Abarrategi A; Waclawiczek A; Ombrato L; Malanchi I; Gribben J; Bonnet D
Cell Rep; 2021 May; 35(6):109119. PubMed ID: 33979628
[TBL] [Abstract][Full Text] [Related]
29. Timer-based proteomic profiling of the ubiquitin-proteasome system reveals a substrate receptor of the GID ubiquitin ligase.
Kong KE; Fischer B; Meurer M; Kats I; Li Z; Rühle F; Barry JD; Kirrmaier D; Chevyreva V; San Luis BJ; Costanzo M; Huber W; Andrews BJ; Boone C; Knop M; Khmelinskii A
Mol Cell; 2021 Jun; 81(11):2460-2476.e11. PubMed ID: 33974913
[TBL] [Abstract][Full Text] [Related]
30. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.
Huttlin EL; Bruckner RJ; Navarrete-Perea J; Cannon JR; Baltier K; Gebreab F; Gygi MP; Thornock A; Zarraga G; Tam S; Szpyt J; Gassaway BM; Panov A; Parzen H; Fu S; Golbazi A; Maenpaa E; Stricker K; Guha Thakurta S; Zhang T; Rad R; Pan J; Nusinow DP; Paulo JA; Schweppe DK; Vaites LP; Harper JW; Gygi SP
Cell; 2021 May; 184(11):3022-3040.e28. PubMed ID: 33961781
[TBL] [Abstract][Full Text] [Related]
31. SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.
Pacharne S; Dovey OM; Cooper JL; Gu M; Friedrich MJ; Rajan SS; Barenboim M; Collord G; Vijayabaskar MS; Ponstingl H; De Braekeleer E; Bautista R; Mazan M; Rad R; Tzelepis K; Wright P; Gozdecka M; Vassiliou GS
Blood Adv; 2021 May; 5(9):2412-2425. PubMed ID: 33956058
[TBL] [Abstract][Full Text] [Related]
32. "Root"ing for successful T-ALL treatment.
Padi SKR; Kraft AS
Blood; 2021 May; 137(18):2422-2423. PubMed ID: 33956068
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials.
Eckert C; Parker C; Moorman AV; Irving JA; Kirschner-Schwabe R; Groeneveld-Krentz S; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Henze G; Chen-Santel C; Attarbaschi A; Bourquin JP; Sramkova L; Zimmermann M; Krishnan S; von Stackelberg A; Saha V
Eur J Cancer; 2021 Jul; 151():175-189. PubMed ID: 34010787
[TBL] [Abstract][Full Text] [Related]
34. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
35. Sox9 and Rbpj differentially regulate endothelial to mesenchymal transition and wound scarring in murine endovascular progenitors.
Zhao J; Patel J; Kaur S; Sim SL; Wong HY; Styke C; Hogan I; Kahler S; Hamilton H; Wadlow R; Dight J; Hashemi G; Sormani L; Roy E; Yoder MC; Francois M; Khosrotehrani K
Nat Commun; 2021 May; 12(1):2564. PubMed ID: 33963183
[TBL] [Abstract][Full Text] [Related]
36. IFN-γ-dependent NK cell activation is essential to metastasis suppression by engineered Salmonella.
Lin Q; Rong L; Jia X; Li R; Yu B; Hu J; Luo X; Badea SR; Xu C; Fu G; Lai K; Lee MC; Zhang B; Gong H; Zhou N; Chen XL; Lin SH; Fu G; Huang JD
Nat Commun; 2021 May; 12(1):2537. PubMed ID: 33953170
[TBL] [Abstract][Full Text] [Related]
37. Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter.
van der Kouwe E; Heller G; Czibere A; Pulikkan JA; Agreiter C; Castilla LH; Delwel R; Di Ruscio A; Ebralidze AK; Forte M; Grebien F; Heyes E; Kazianka L; Klinger J; Kornauth C; Le T; Lind K; Barbosa IAM; Pemovska T; Pichler A; Schmolke AS; Schweicker CM; Sill H; Sperr WR; Spittler A; Surapally S; Trinh BQ; Valent P; Vanura K; Welner RS; Zuber J; Tenen DG; Staber PB
Blood; 2021 Oct; 138(15):1345-1358. PubMed ID: 34010414
[TBL] [Abstract][Full Text] [Related]
38. Towards precision medicine for AML.
Döhner H; Wei AH; Löwenberg B
Nat Rev Clin Oncol; 2021 Sep; 18(9):577-590. PubMed ID: 34006997
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer.
Gupta VK; Sharma NS; Durden B; Garrido VT; Kesh K; Edwards D; Wang D; Myer C; Mateo-Victoriano B; Kollala SS; Ban Y; Gao Z; Bhattacharya SK; Saluja A; Singh PK; Banerjee S
Cancer Res; 2021 Aug; 81(15):4001-4013. PubMed ID: 33990397
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
Libiger O; Shaw LM; Watson MH; Nairn AC; Umaña KL; Biarnes MC; Canet-Avilés RM; Jack CR; Breton YA; Cortes L; Chelsky D; Spellman DS; Baker SA; Raghavan N; Potter WZ; ;
Alzheimers Dement; 2021 Dec; 17(12):1976-1987. PubMed ID: 33984181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
